Inyx Selected by U.K. Client to Produce Novel HFA Aerosol Urological Product for U.S. Phase III Trial

NEW YORK, July 20  /PRNewswire-FirstCall/ -- Inyx, Inc. (OTC:IYXI) (BULLETIN BOARD: IYXI) , a specialty pharmaceutical company focused on niche drug delivery technologies and products, announced today that its wholly owned subsidiary, Inyx USA Ltd., has been selected by an emerging U.K. specialty pharmaceutical company to manufacture a novel urological product as a topical HFA (hydrofluroalkane) aerosol spray for Phase III trial in the U.S.

Inyx USA will initially provide process transfer services to enable production of the clinical-trial batches at an enhanced HFA facility at its Manati site in Puerto Rico.  Inyx USA will produce both active and placebo batches for the trial.

Jack Kachkar, M.D., Chairman of Inyx, Inc., said, "We are very pleased that a new, U.K.-based client has selected Inyx USA for Phase III trial production.  This selection reflects our intensifying, coordinated business development efforts from both sides of the Atlantic."

Last year, Inyx acquired the Puerto Rico site from Sanofi-Aventis, giving Inyx an operating base in the United States.  The Manati complex, located in north central Puerto Rico about 30 miles outside of San Juan, extends over 9.5 acres and presently consists of five buildings totaling approximately 140,000 square feet.

About Inyx

Inyx, Inc. is a specialty pharmaceutical company with niche drug delivery technologies and products for the treatment of respiratory, allergy, dermatological, topical and cardiovascular conditions.  Inyx focuses its expertise on both prescription and over-the-counter pharmaceutical products, and provides specialty pharmaceutical development and production consulting services.  In addition, Inyx is developing its own proprietary products.  The company's operations are conducted through several wholly owned subsidiaries: Inyx USA Ltd., based in Manati, Puerto Rico; Inyx Pharma Ltd. and Inyx Europe Limited, which owns and operates Ashton Pharmaceuticals Ltd., all near Manchester, England; Inyx Canada, Inc. in Toronto; and Exaeris, Inc., based in Exton, Pennsylvania, which conducts Inyx's marketing and distribution activities.  Inyx, Inc.'s corporate offices are in New York City.  For more information, please visit:  http://www.inyxgroup.com/.

Safe Harbor

Statements about the Inyx's future expectations, including future revenues and earnings, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995.  Inyx intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, Inyx's actual results could differ materially from expected results.

  For more information, please contact:
  Jay M. Green, Executive Vice President of Inyx, Inc.
  

  Bill Kelly, Vice President Investor Relations of Inyx, Inc.
  

DATASOURCE: Inyx, Inc.



CONTACT:  Jay M. Green, Executive Vice President, ,

or Bill Kelly, Vice President Investor Relations, ,

both of Inyx, Inc. 



Web site:  http://www.inyxinc.com/

Copyright